344 related articles for article (PubMed ID: 23017225)
21. Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia.
Pei R; Cao J; Ma J; Zhang P; Liu X; Du X; Chen D; Sha K; Chen L; Li S; Wu J; Fan Z; Lin L; Ye P; Tang S; Zhang B
Hematology; 2012 Nov; 17(6):311-6. PubMed ID: 23168069
[TBL] [Abstract][Full Text] [Related]
22. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
[TBL] [Abstract][Full Text] [Related]
23. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
[TBL] [Abstract][Full Text] [Related]
24. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
[TBL] [Abstract][Full Text] [Related]
25. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
26. How to manage acute promyelocytic leukemia.
Mi JQ; Li JM; Shen ZX; Chen SJ; Chen Z
Leukemia; 2012 Aug; 26(8):1743-51. PubMed ID: 22422168
[TBL] [Abstract][Full Text] [Related]
27. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
[TBL] [Abstract][Full Text] [Related]
28. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
[TBL] [Abstract][Full Text] [Related]
29. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M
Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972
[TBL] [Abstract][Full Text] [Related]
30. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
31. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
Lachaine J; Mathurin K; Barakat S; Couban S
Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of acute promyelocytic leukemia treated with all-
Abaza Y; Kantarjian H; Garcia-Manero G; Estey E; Borthakur G; Jabbour E; Faderl S; O'Brien S; Wierda W; Pierce S; Brandt M; McCue D; Luthra R; Patel K; Kornblau S; Kadia T; Daver N; DiNardo C; Jain N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Estrov Z; Foudray M; McCue D; Cortes J; Ravandi F
Blood; 2017 Mar; 129(10):1275-1283. PubMed ID: 28003274
[TBL] [Abstract][Full Text] [Related]
33. Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).
Gupta V; Yi QL; Brandwein J; Lipton JH; Messner HA; Schuh AC; Wells RA; Minden MD
Leuk Res; 2005 Jan; 29(1):113-4. PubMed ID: 15541484
[TBL] [Abstract][Full Text] [Related]
34. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Ravandi F; Estey E; Jones D; Faderl S; O'Brien S; Fiorentino J; Pierce S; Blamble D; Estrov Z; Wierda W; Ferrajoli A; Verstovsek S; Garcia-Manero G; Cortes J; Kantarjian H
J Clin Oncol; 2009 Feb; 27(4):504-10. PubMed ID: 19075265
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
Ghavamzadeh A; Alimoghaddam K; Rostami S; Ghaffari SH; Jahani M; Iravani M; Mousavi SA; Bahar B; Jalili M
J Clin Oncol; 2011 Jul; 29(20):2753-7. PubMed ID: 21646615
[TBL] [Abstract][Full Text] [Related]
36. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Aribi A; Kantarjian HM; Estey EH; Koller CA; Thomas DA; Kornblau SM; Faderl SH; Laddie NM; Garcia-Manero G; Cortes JE
Cancer; 2007 Apr; 109(7):1355-9. PubMed ID: 17326049
[TBL] [Abstract][Full Text] [Related]
38. Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia.
Jiang H; Liang GW; Huang XJ; Jiang Q; Han S; Shi LW; Zhu HH
Leuk Res; 2015 Dec; 39(12):1319-24. PubMed ID: 26403986
[TBL] [Abstract][Full Text] [Related]
39. ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.
Long ZJ; Hu Y; Li XD; He Y; Xiao RZ; Fang ZG; Wang DN; Liu JJ; Yan JS; Huang RW; Lin DJ; Liu Q
PLoS One; 2014; 9(8):e104610. PubMed ID: 25122165
[TBL] [Abstract][Full Text] [Related]
40. Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy.
Lou Y; Suo S; Tong Y; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Jin J
Ann Hematol; 2014 Jun; 93(6):941-8. PubMed ID: 24408159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
